Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Theriva Biologics (TOVX)
NYSE MKT:TOVX
Holding TOVX?
Track your performance easily
TOVX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.22 - $17.11
Previous Close$1.44
Volume61.55K
Average Volume (3M)2.95M
Market Cap
$4.01M
Enterprise Value-$10.66M
Total Cash (Recent Filing)$16.41M
Total Debt (Recent Filing)$1.74M
Price to Earnings (P/E)―
Beta1.86
Next Earnings
Feb 27, 2025EPS Estimate
-$7.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-33.06
Shares Outstanding2,782,449
10 Day Avg. Volume257,408
30 Day Avg. Volume2,949,510
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)0.14
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-10.00T>
Enterprise Value/Ebitda0.55
Forecast
1Y Price Target
$6.00Price Target Upside316.67% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Theriva Biologics News
PremiumCompany Announcements
Theriva Biologics Advances VCN-01 with FDA Guidance
PremiumCompany Announcements
Theriva Biologics Highlights Key Achievements in Q3 2024
PremiumMarket News
3 Penny Stocks to Watch Now, 11/5/24
PremiumCompany Announcements
Theriva Biologics Expands Stock Plans and Share AuthorityBulls Say, Bears Say
Bulls Say
Clinical Trial ResultsThe P2b VIRAGE pancreatic cancer study is evaluating VCN-01 with chemotherapy, and the prior P1 study showed a 20.8-month overall survival and an 83% overall response rate, which compares favorably to chemotherapy alone.
Promising Treatment For RetinoblastomaVCN-01 is also being evaluated for the treatment of advanced retinoblastoma, and it has shown promising results in reducing tumor size and even complete regression in some patients in a prior P1 study.
Regulatory DesignationsVCN-01 has orphan drug designation for treatment of pancreatic cancer as well as fast track designation.
Bears Say
Capital RaisingThe next capital raise for Theriva Biologics could be significantly dilutive given the challenging financing environment for biotech companies.
EarningsTheriva reported 2Q24 results and filed its 10-Q with a net loss of ($8.3M) and ended the period with $16.6M in cash on the balance sheet.
Financial PerformanceThe commercialization timelines for VCN-01 have been extended to 2030, which has contributed to lowering the price target.
---
Ownership Overview
9.37%
Insiders
0.44% Mutual Funds
14.68% Other Institutional Investors
75.23% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
TOVX FAQ
What was Theriva Biologics’s price range in the past 12 months?
Theriva Biologics lowest stock price was $1.22 and its highest was $17.11 in the past 12 months.
What is Theriva Biologics’s market cap?
Currently, no data Available
When is Theriva Biologics’s upcoming earnings report date?
Theriva Biologics’s upcoming earnings report date is Feb 27, 2025 which is in 71 days.
How were Theriva Biologics’s earnings last quarter?
Theriva Biologics released its earnings results on Nov 12, 2024. The company reported -$6.81 earnings per share for the quarter, missing the consensus estimate of -$6.25 by -$0.56.
Is Theriva Biologics overvalued?
According to Wall Street analysts Theriva Biologics’s price is currently Undervalued.
Does Theriva Biologics pay dividends?
Theriva Biologics does not currently pay dividends.
What is Theriva Biologics’s EPS estimate?
Theriva Biologics’s EPS estimate is -$7.22.
How many shares outstanding does Theriva Biologics have?
Theriva Biologics has 2,782,449 shares outstanding.
What happened to Theriva Biologics’s price movement after its last earnings report?
Theriva Biologics reported an EPS of -$6.81 in its last earnings report, missing expectations of -$6.25. Following the earnings report the stock price went down -23.118%.
Which hedge fund is a major shareholder of Theriva Biologics?
Among the largest hedge funds holding Theriva Biologics’s share is Fisher Asset Management LLC. It holds Theriva Biologics’s shares valued at N/A.
---
Theriva Biologics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$6.00 (316.67% Upside)
$6.00 (316.67% Upside)
Hedge Fund Trend
Decreased
By 502.0 Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.1%
Last 30 Days ▼ 8.8%
Last 30 Days ▼ 8.8%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-90.07%
12-Months-Change
Fundamentals
Return on Equity
-77.91%
Trailing 12-Months
Asset Growth
-34.83%
Trailing 12-Months
Company Description
Theriva Biologics
Synthetic Biologics, Inc. is a clinical stage company, which engages in the development of therapeutics to preserve the microbiome to protect and restore the health of patients. Its product portfolio includes SYN-010 and SYN-004. The SYN-010, which is intended to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation. The SYN-004, which is designed to protect the gut microbiome from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C. difficile infection, antibiotic-associated diarrhea, and the emergence of antimicrobial resistance. The company was founded by Steven H. Kanzer in January 2001 and is headquartered in Rockville, MD.
---
TOVX Earnings Call
Q4 2024
0:00 / 0:00
---
TOVX Stock 12 Month Forecast
Average Price Target
$6.00
▲(316.67% Upside)
Technical Analysis
Best Analysts Covering TOVX
1 Year
1 Year Success Rate
1/9 ratings generated profit
1 Year Average Return
-58.12%
reiterated a buy rating last month
Copying Jason McCarthy's trades and holding each position for 1 Year would result in 11.11% of your transactions generating a profit, with an average return of -58.12% per trade.
---